Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin versus pioglitazone for cardiac effects in type 2 diabetes with NAFLD
IRCT20190122042450N5Phase 2Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, triple-blind trial in type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatotic liver disease (MASLD) comparing Empagliflozin with Pioglitazone (2 arms). Primary endpoint: Echocardiographic indices. Started Oct 2020; status: completed.
02
Drugs
empagliflozinpioglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on IRCT20190122042450N5.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190122042450N5.